Corneal permeation studies of everolimus microemulsion

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 4, 2008, Pages 399-402

  Baspinar, Yuecel ^a   Bertelmann, Eckart ^b   Pleyer, Uwe ^b   Buech, Guido ^a   Siebenbrodt, Ingo ^a   Borchert, Hans Hubert ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; EX VIVO STUDY; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROEMULSION; NONHUMAN; SWINE;

ANIMALS; CORNEA; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; PERMEABILITY; SIROLIMUS; SWINE;

EID: 48349083421     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0088     Document Type: Article

References (23)

1. Joseph, A., Raj, D., Shanmuganathan, V., et al. Tacrolimus immunosuppression in high-risk corneal grafts. Br. J. Ophthalmol. 91:51-55, 2006.
2. Scheer, S., Touzeau, O., Borderie, V., et al. Immunosuppression in corneal transplantation. J. Fran. Ophthalmol. 26:637-647, 2003.
3. Olsen, T.W., Benegas, N.M., Joplin, A.C., et al. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch. Ophthalmol. 112:1471-1475, 1994.
4. Dejneka, N.S., Kuroki, M.A., Fosnot, J., et al. Sytemic rapamycin inhibits retinal and choroidal neovascularisation in mice. Mol. Vis. 10:964-972, 2004.
5. Thompson, P., Xu, D., Brunette, I., et al. Combined effect of rapamycin and cyclosporin in the prevention of rat corneal allograft rejection. Transpl. Proc. 30:1033-1035, 1998.
6. Reis, A., Megahed, M., Reinhard, T., et al. RAD, a new immunosuppressive macrolide in murine corneal transplantation. Graefe's Arch. Clin. Exp. Ophthalmol. 239:689-692, 2001.
7. Reis, A., Megahed, M., Reinhard, T., et al. Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21:81-84, 2002.
8. Stumpf, T., Luqmani, N., Sumich, P., et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 25:1147-1149, 2006.
9. Buech, G., Bertelmann, E., Pleyer, U., et al. Formulation of sirolimus eye drops and corneal permeation studies. J. Ocul. Pharmacol. Ther. 23:292-303, 2007.
10. Kovarik, J.M., Tedesco, H., Pascual, J., et al. Everolimus therapeutic concentration range defined from a prospective trial with a reduced-exposure cyclosporine in de novo kidney transplantation. Ther. Drug Monit. 26:499-505, 2004.
11. Starling, R.C., Hare, J.M., Hauptmann, P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am. J. Transpl. 4:2126-2131, 2004.
12. Siebenbrodt, I., and Keipert, S. Poloxamer-systems as potential ophthalmics II. Microemulsions. Eur. J. Pharm. Biopharm. 39:25-30, 1993.
13. Leaf, C.W. Toxicology of some nonionic surfactants. Soaps Chem. Spec. 43:48-51, 106, 108-110, 1967.
14. Grant, M.S. Toxicology of the Eye. Springfield, IL: Charles C. Thomas, 1993.
15. Laillier, J., Plazonnet, B., and Le Douarec, J.C., Evaluation of ocular irritation in the rabbit: Development of an objective method of studying eye irritation. Proc. Eur. Soc. Toxicol. 17:336-350, 1976.
16. Concuet, P., Durand, G., Laillier, J., et al. Evaluation of ocular eye irritation in the rabbit. Objective versus subjective assessment. Tox. App. Pharmacol. 39:29-139, 1977.
17. Bietti, G.B., Virno, M., and Pecori-Giraldi, J. Propylenglycol, a new osmotic agent for ophthalmic uses. Documenta. Ophthalmol. 34:77-92, 1973.
18. Luepke, N.P. Hen's egg chorio allantoinic membrane test for irritation potential. Fd. Chem. Tox. 23:287-291, 1985.
19. Luepke, N.P., and Kemper, F.H. The HET-CAM test: An alternative to the Draize eye test. Fd. Chem. Tox. 24:495-496, 1986.
20. Spielmann, H., Liebsch, M., Kalweit, S., et al. Results of a validation study in Germany on two in vitro alternatives to the Draize eye irritation test, the HET-CAM test, and the 3T3 NRU cytotoxicity test. ALAT 24:741-858, 1996.
21. Svensson, J.O., Brattström, C., and Säwe, J. Determination of rapamycin in whole blood by HPLC. Ther. Drug Monit. 19:112-116, 1997.
22. Siefert, B., and Keipert, S. Influence of alpha-cyclodextrin and hydroxyalkylated betacyclodextrin derivatives on the in vivo corneal uptake and permeation of aqueous pilocarpine-HCl solutions. J. Pharm. Sci. 86:716-720, 1997.
23. Kirchner, G.I., Meier-Wiedenbach, I., and Manns, M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43:83-95, 2004.